TABLE 3.
Loss in activity for ABT-450 against resistant variants selected by NS3/4A protease inhibitors
| Replicona | NS3 variant | Fold change in EC50 relative to wild-type value | Replication capacity (% of wild-type level) |
|---|---|---|---|
| 1a-H77 | V36A | 3 | 130 |
| V36L | 2 | 82 | |
| V36M | 2 | 81 | |
| F43L | 20 | 17 | |
| T54S | 0.4 | 6 | |
| V55I | 1 | 81 | |
| Q80K | 3 | 91 | |
| Q80L | 2 | 38 | |
| Q80R | 2 | 44 | |
| R155G | 14 | 2 | |
| R155Kb | 37 | 31 | |
| R155S | 7 | 2 | |
| R155T | 7 | 5 | |
| R155W | 11 | 5 | |
| A156T | 17 | 5 | |
| D168A | 50 | 35 | |
| D168Eb | 14 | 34 | |
| D168H | 62 | 24 | |
| D168Nb | 13 | 28 | |
| D168V | 96 | 2 | |
| D168Y | 219 | 4 | |
| V36M + R155K | 79 | 29 | |
| Q80K + R155K | 19 | 77 | |
| 1b-Con1 | T54A | 1 | 59 |
| V55A | 1 | 14 | |
| R155K | 40 | 73 | |
| R155Qb | <0.5 | ||
| A156S | 0.5 | 61 | |
| A156Tb | 7 | 19 | |
| D168A | 27 | 69 | |
| D168E | 4 | 80 | |
| D168Hb | 76 | 108 | |
| D168T | 49 | 129 | |
| D168Vb | 159 | 157 | |
| D168Yb | 337 | 70 | |
| V170A | 1 | 64 |